UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 10.

Wick, W; Roth, P; Hartmann, C; Hau, P; Nakamura, M; Stockhammer, F; Sabel, M C; Wick, A; Koeppen, S; Ketter, R; Vajkoczy, P; Eyupoglu, I; Kalff, R; Pietsch, T; Happold, C; Galldiks, N; Schmidt-Graf, F; Bamberg, M; Reifenberger, G; Platten, M; von Deimling, A; Meisner, C; Wiestler, B; Weller, M (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18(11):1529-1537.

Suchorska, B; Weller, M; Tabatabai, G; Senft, C; Hau, P; Sabel, M C; Herrlinger, U; Ketter, R; Schlegel, U; Marosi, C; Reifenberger, G; Wick, W; Tonn, J C; Wirsching, H G (2016). Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology, 18(4):549-556.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Mossong, J; DeCruyenaere, F; Moris, G; Ragimbeau, C; Olinger, Ch; Johler, Sophia; Perrin, M; Hau, P; Weicherding, P (2015). Investigation of a staphylococcal food poisoning outbreak combining case–control, traditional typing and whole genome sequencing methods, Luxembourg, June 2014. Eurosurveillance, 20(45):pii=30059.

Riemenschneider, M J; Louis, D N; Weller, M; Hau, P (2013). Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. Acta Neuropathologica, 126(1):21-37.

Grauer, O; Pascher, C; Hartmann, C; Zeman, F; Weller, M; Proescholdt, M; Brawanski, A; Pietsch, T; Wick, W; Bogdahn, U; Hau, P (2011). Erratum to: Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). Journal of Neuro-Oncology, 105(3):671.

Grauer, O; Pascher, C; Hartmann, C; Zeman, F; Weller, M; Proescholdt, M; Brawanski, A; Pietsch, T; Wick, W; Bogdahn, U; Hau, P (2011). Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). Journal of Neuro-Oncology, 104(3):801-809.

Pels, H; Juergens, A; Glasmacher, A; Schulz, H; Engert, A; Linnebank, M; Schackert, G; Reichmann, H; Kroschinsky, F; Vogt-Schaden, M; Egerer, G; Bode, U; Schaller, C; Lamprecht, M; Hau, P; Deckert, M; Fimmers, R; Bangard, C; Schmidt-Wolf, G; Schlegel, U (2009). Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. Journal of Neuro-Oncology, 91(3):299-305.

Stupp, R; Hegi, M E; Mason, W P; van den Bent, M J; Taphoorn, M J B; Janzer, R C; Ludwin, S K; Allgeier, A; Fisher, B; Belanger, K; Hau, P; Brandes, A A; Gijtenbeek, J; Marosi, C; Vecht, C J; Mokhtari, K; Wesseling, P; Villa, S; Eisenhauer, E; Gorlia, T; Weller, M; Lacombe, D; Cairncross, J G; Mirimanoff, R O (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5):459-466.

Wick, A; Pascher, C; Wick, W; Jauch, T; Weller, M; Bogdahn, U; Hau, P (2009). Rechallenge with temozolomide in patients with recurrent gliomas. Journal of Neurology, 256(5):734-741.

This list was generated on Sun Jul 23 04:49:07 2017 CEST.